Page 37 - Gates-AnnualReport-2018

My vision is a seamless transition between Anschutz and Boulder. We do not plan to generate iPSCs – you do this extremely well and the patient resources are at Anschutz – but instead to expand the scope of iPSC studies by creating a hub in Boulder for life scientists with new biological insights and to develop innovative platforms alongside engineers for differentiation and organoid formation. Then, when projects move forward to potential clinical application, this would pass back down to Anschutz and the GMP facility.
- Lee Niswander, Ph.D.
FOLLOWING IS A LIST OF SOME OF THE CLIENTS WITH WHICH THE CORE HAS COLLABORATED DURING 2018:
ANSCHUTZ MEDICAL CAMPUS
Linda Crnic Institute for Downs Syndrome: iPSCs from renal epithelium: differentiate into different adult lineages
Mike Verneris, M.D.: iPSCs from renal epithelium: differentiate into natural killer cells
Jeffrey Jacot, Ph.D.: iPSCs from cells isolated from amniotic fluid: differentiate in cardiomyocytes
Holger Russ, Ph.D.: iPSCs from thymic epithelium: differentiate into thymic epithelium
Peter Dempsey, Ph.D.: iPSCs from fibroblasts: differentiate into intestinal organoids
Valeria Canto-Soler, Ph.D.: iPSCs from fibroblasts: differentiate into miniature human retinas that sense light Huntington Potter, Ph.D.: iPSC lines from patients with Alzheimer ’s disease: differentiate into neurons to model a neuronal phenotype in Alzheimer’s
Tim Benke, M.D., Ph.D.: iPSCs from patients with specific neurogenetic diseases (epilepsy)* **
Ellen Elias, M.D.: iPSCs from patients with Ehlers-Danlos Syndrome *
Susan Boackle, M.D.: iPSCs from patients with lupus to elucidate the role of specific nucleotide polymorphisms in disease progression
BOULDER CAMPUS CLIENTS
Lee Niswander, Ph.D.: A new Stem Cell Research and Technology Resource Center the goal of which is to expand the scope of iPSC studies by creating a hub in Boulder for life scientists to develop innovative platforms alongside engineers for differentiation and organoid formation.
William Old, Ph.D.: iPSCs from individuals with Down Syndrome and iPSC lines with DYRK1A knockout: differentiate into neuronal organoids
Michael Stowell, Ph.D.: iPSCs from individuals with Alzheimer’s Disease: differentiate into neurons, astrocytes and neuronal organoids
EXTERNAL CLIENTS
Bertha Chen, M.D., and Vittorio Sebastiano, Ph.D. (Stanford): RNA reagents for the production of iPSCs to treat women with urinary incontinence (CIRM funded)
Vittorio Sebastiano, Ph.D. (Stanford): RNA reagents to achieve tissue rejuvenation
Clifford Folmes, Ph.D. (Mayo Clinic Cancer Center, Arizona): Reprogramming RNA reagents and iPSCs to assess changes in mitochondria metabolism during cellular reprogramming
Alain Hovnanian, M.D., Ph.D. (University Paris Descartes - Sorbonne Paris Cité, Paris, France): RNA reagents to generate genetically corrected iPSCs for the treatment of skin blistering diseases
Tony Oro, M.D., Ph.D. and Angela Christiano, Ph.D. (EB iPS Cell Consortium, Stanford and Columbia Universities): RNA reagents to generate genetically corrected iPSCs for the treatment of skin blistering diseases *
* Projects funded through philanthropic donations to the iPSC Discovery Platform ** Project partially funded through the Director’s Innovation Fund
Gates Center for Regenerative Medicine 37